NYC Healthcare News



Loyola University forms new institute for molecular level disease research

October 22, 2015

"Sometimes advancements and understandings in one area are applicable to another. For instance, medication developed for Alzheimer's disease also turned out to be useful in the treatment of some cancers," Patel said. "If we can get people from different research areas to talk to each other, we can bring novel ideas from different areas to different people and synergize our progress toward understanding and treating diseases."

Membership in the institute is open to all Stritch faculty, physicians and researchers who are exploring or plan to explore signaling mechanisms related to all areas of biomedical research. The initial goals of the institute will be to help generate additional grants for research, provide additional infrastructure, establish specialized degree programs and curricula for graduate students and to foster productive collaboration with the private sector.

"Signal transduction research is a major area of focus in the academic and medical communities," said Richard L. Gamelli, MD, FACS, dean of the Stritch School of Medicine and senior vice president of Loyola University Health System. "The close collaboration within the Institute of Signal Transduction will be vital to the overall integration of Loyola's research and patient-care efforts."

SOURCE Loyola University Chicago